Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Total Valuation
Akebia Therapeutics has a market cap or net worth of $478.05M. The enterprise value is $434.77M.
Market Cap$478.05M
Enterprise Value$434.77M
Share Statistics
Akebia Therapeutics has 261.23M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding261.23M
Owned by Insiders11.33%
Owned by Instutions0.10%
Financial Efficiency
Akebia Therapeutics’s return on equity (ROE) is 1.41 and return on invested capital (ROIC) is -36.11%.
Return on Equity (ROE)141.12%
Return on Assets (ROA)-31.45%
Return on Invested Capital (ROIC)-36.11%
Return on Capital Employed (ROCE)-36.11%
Revenue Per Employee$884,972.376
Profits Per Employee-$383,480.663
Employee Count181
Asset Turnover0.73
Inventory Turnover3.89
Valuation Ratios
The current PE Ratio of Akebia Therapeutics is -5.77. Akebia Therapeutics’s PEG ratio is -0.32.
PE Ratio-5.77
PS Ratio2.50
PB Ratio-8.15
Price to Fair Value-8.15
Price to FCF-9.85
Price to Operating Cash Flow-9.86
PEG Ratio-0.32
Income Statement
In the last 12 months, Akebia Therapeutics had revenue of $160.18M and earned -$69.41M in profits. Earnings per share was -$0.34.
Revenue$160.18M
Gross Profit$96.24M
Operating Income-$50.41M
Pretax Income-$69.41M
Net Income-$69.41M
EBITDA-13.72M
Earnings Per Share (EPS)-0.34
Cash Flow
In the last 12 months, operating cash flow was -$40.66M and capital expenditures -$2.00K, giving a free cash flow of -$40.66M billion.
Operating Cash Flow-$40.66M
Free Cash Flow-$40.66M
Free Cash Flow per Share-$0.16
Dividends & Yields
Akebia Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-10.15%
Earnings Yield-17.32%
Stock Price Statistics
Beta1.49
52-Week Price Change35.00%
50-Day Moving Average1.96
200-Day Moving Average1.70
Relative Strength Index (RSI)50.22
Average Volume (3m)5.59M
Important Dates
Akebia Therapeutics upcoming earnings date is May 12, 2025, After Close.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Akebia Therapeutics as a current ratio of 1.41, with Debt / Equity ratio of -0.07
Current Ratio1.41
Quick Ratio1.21
Debt to Market Cap<0.01
Net Debt to EBITDA3.52
Interest Coverage Ratio-2.78
Taxes
In the past 12 months, Akebia Therapeutics has paid $9.33M in taxes.
Income Tax$9.33M
Effective Tax Rate0.00%
Enterprise Valuation
Akebia Therapeutics EV to EBITDA ratio is -25.69, with an EV/FCF ratio of -8.66.
EV to Sales2.20
EV to EBITDA-25.69
EV to Free Cash Flow-8.66
EV to Operating Cash Flow-8.67
Balance Sheet
Akebia Therapeutics has $51.87M in cash and marketable securities with $47.64M in debt, giving a net cash position of -$4.23M billion.
Cash & Marketable Securities$51.87M
Total Debt$47.64M
Net Cash-$4.23M
Net Cash Per Share-$0.02
Tangible Book Value Per Share-$0.51
Margins
Gross margin is 60.56%, with operating margin of -31.51%, and net profit margin of -43.33%.
Gross Margin60.56%
Operating Margin-31.51%
Pretax Margin-43.33%
Net Profit Margin-43.33%
EBITDA Margin-8.57%
EBIT Margin-31.98%
Analyst Forecast
The average price target for Akebia Therapeutics is $7.38, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.38
Price Target Upside290.48%
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-17.75%
EPS Growth Forecast-19.17%